VenoValve Cost-Effectiveness Study Shows Potential $5.9 Billion Annual Savings in Healthcare Costs for Severe Chronic Venous Insufficiency Patients

A health economic study has found that enVVeno Medical's VenoValve would be a cost-effective treatment option for patients with severe chronic venous insufficiency. The VenoValve could potentially save $5.9 billion annually in healthcare costs for the approximately 2.5 million U.S. patients with severe CVI. The study showed that the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatments.

A recent health economic study has revealed that enVVeno Medical's VenoValve could be a cost-effective treatment option for patients with severe chronic venous insufficiency (CVI). The study, conducted by enVVeno Medical, demonstrated that the VenoValve could potentially save $5.9 billion annually in healthcare costs for approximately 2.5 million U.S. patients with severe CVI [1].

The study found that the VenoValve would provide better health outcomes and lower costs compared to current standard of care treatments. Key clinical benefits included avoiding 2.2 ulcers per patient and gaining 0.33 additional quality-adjusted life years (QALYs) over a five-year period. The device achieved cost break-even within 2-3 years, making it a favorable option for commercial payers [1].

The study also highlighted the substantial market potential for the VenoValve, with an addressable market of approximately 2.5 million patients in the U.S., including 1.5 million diagnosed with venous ulcers. The economic validation complements the previously reported clinical data from the VenoValve's pivotal trial, creating a compelling case for adoption [1].

The FDA decision on the VenoValve's Pre-Market Authorization (PMA) application is expected in the second half of 2025. The health economic findings significantly strengthen enVVeno's commercialization prospects by addressing payer willingness to cover costs, a major hurdle to widespread adoption [1].

References:
[1] https://www.stocktitan.net/news/NVNO/health-economic-study-shows-that-en-v-veno-medical-s-veno-valve-r-5rkzusse3211.html